Cytokinetics stock is trading -39.43% below its average target price of $80.69 after marking a 4.6% during today's afternoon session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $60.0 to $120.0 per share.
Cytokinetics has an elevated short interest of 18.1%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 10.52. Only 0.54% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 118.2% of Cytokinetics shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Cytokinetics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 13% | 15,252,839 | $745,406,225 |
| 2024-09-30 | FMR, LLC | 10% | 12,094,254 | $591,046,180 |
| 2024-09-30 | Vanguard Group Inc | 10% | 11,761,605 | $574,789,623 |
| 2024-09-30 | T. Rowe Price Investment Management, Inc. | 8% | 9,689,987 | $473,549,654 |
| 2024-09-30 | Wellington Management Group, LLP | 7% | 7,774,970 | $379,962,775 |
| 2024-09-30 | State Street Corporation | 5% | 6,458,324 | $315,618,286 |
| 2024-09-30 | Bank of America Corporation | 4% | 4,829,423 | $236,013,896 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 3% | 3,164,945 | $154,670,858 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 2,848,584 | $139,210,297 |
| 2024-09-30 | RTW Investments LP | 2% | 2,721,158 | $132,982,988 |
For these reasons, we consider that the Cytokinetics is the subject of mixed market sentiment.
